Stomach

• (101-21) A Phase 1 Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic, Pharmacokinetic Study of Q702 with a Cohort Expansion at the RP2D in Patients with Advanced Solid Tumors
• (106-19) A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastroesophageal Adenocarcinoma
• (107-19) A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
• (114-19) A Phase 1, open label, first-in-human study of TR1801-ADC, an antibody drug conjugate (ADC), in patients with select solid tumors expressing c-Met

• (155-17) 0C 17-1: Phase 1 Multi-center Study of the Safety Pharmacokinetics and Preliminary Efficacy of CBT-101 in Subjects with Advanced Solid Tumors and C-Met Dysregulation

• (178-18) A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors

• (180-18) AO-176 in Multiple Solid Tumor Malignancies

• (187-17) Trial of ZW25 in Patients With Advanced HER2-expressing Cancers
• (187-19) A Phase 1/2 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination With AGEN2034, an Anti-PD-1 Monoclonal Antibody, in Subjects with Advanced Cancer

• (189-18) ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With Metastatic Solid Tumors

• (205-19) Study to Assess AFM24 in Advanced Solid Cancers

• (207-20) An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects with Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

• (221-19) Study of GNX102 in Patients With Advanced Solid Tumors

Certain clinical trials may not be listed on ClinicalTrials.gov. To learn more about these or other clinical trials, please call 949-764-5543 or contact us online.